ATE404698T1 - Methode zur bestimmung der resistenz gegen medikamente - Google Patents

Methode zur bestimmung der resistenz gegen medikamente

Info

Publication number
ATE404698T1
ATE404698T1 AT01933853T AT01933853T ATE404698T1 AT E404698 T1 ATE404698 T1 AT E404698T1 AT 01933853 T AT01933853 T AT 01933853T AT 01933853 T AT01933853 T AT 01933853T AT E404698 T1 ATE404698 T1 AT E404698T1
Authority
AT
Austria
Prior art keywords
phenotype
drugs
patient
database
resistance
Prior art date
Application number
AT01933853T
Other languages
English (en)
Inventor
Brendan Larder
Stuart Bloor
Kurt Hertogs
Pascale Dehertogh
Rudy Mortier
Original Assignee
Virco Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virco Bvba filed Critical Virco Bvba
Application granted granted Critical
Publication of ATE404698T1 publication Critical patent/ATE404698T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/20—Heterogeneous data integration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Artificial Intelligence (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT01933853T 2000-04-18 2001-04-18 Methode zur bestimmung der resistenz gegen medikamente ATE404698T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19760600P 2000-04-18 2000-04-18
US21321900P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
ATE404698T1 true ATE404698T1 (de) 2008-08-15

Family

ID=26892992

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08160749T ATE526423T1 (de) 2000-04-18 2001-04-18 Verfahren zum messen des medikamentenwiderstands gegen hcv
AT01933853T ATE404698T1 (de) 2000-04-18 2001-04-18 Methode zur bestimmung der resistenz gegen medikamente

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08160749T ATE526423T1 (de) 2000-04-18 2001-04-18 Verfahren zum messen des medikamentenwiderstands gegen hcv

Country Status (9)

Country Link
US (3) US20040137436A1 (de)
EP (2) EP2011889B1 (de)
JP (1) JP5156163B2 (de)
AT (2) ATE526423T1 (de)
AU (1) AU2001260224A1 (de)
CA (1) CA2406140A1 (de)
DE (1) DE60135366D1 (de)
ES (2) ES2373488T3 (de)
WO (1) WO2001079540A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4248593A (en) * 1992-05-14 1993-12-13 Mark Holodniy Polymerase chain reaction assays for monitoring antiviral therapy
US6968375B1 (en) * 1997-03-28 2005-11-22 Health Hero Network, Inc. Networked system for interactive communication and remote monitoring of individuals
US20040072722A1 (en) * 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
US20040023375A1 (en) 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
AU2002226316B2 (en) 2000-10-20 2008-06-26 Virco Bvba Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
WO2003040390A2 (en) 2001-11-08 2003-05-15 Tibotec Pharmaceuticals Ltd. Protease assay for therapeutic drug monitoring
AU2002360532A1 (en) * 2001-12-10 2003-06-23 Ardais Corporation Systems and methods for obtaining data correlated patient samples
JP4041842B2 (ja) * 2002-01-15 2008-02-06 デジタル・インフォメーション・テクノロジー株式会社 Ｓｎｐ特定方法
ATE423785T1 (de) * 2002-03-11 2009-03-15 Lab 21 Ltd Verfahren und zusammensetzungen zur identifikation und charakterisierung von hepatitis c
EP1522039B1 (de) 2002-07-01 2008-06-04 Tibotec Pharmaceuticals Ltd. Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
AU2003254500B2 (en) * 2002-07-01 2009-11-19 Tibotec Pharmaceuticals Ltd. Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
US8463441B2 (en) 2002-12-09 2013-06-11 Hudson Technologies, Inc. Method and apparatus for optimizing refrigeration systems
US8688385B2 (en) * 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
DK1599576T3 (en) 2003-02-20 2016-08-01 Mayo Foundation Methods for selecting antidepressants
DE10324045B3 (de) * 2003-05-27 2004-10-14 Siemens Ag Verfahren sowie Computerprogramm mit Programmcode-Mitteln und Computerprogramm-Produkt zur Ermittlung eines zukünftigen Systemverhaltens eines dynamischen Systems
WO2004111907A2 (en) * 2003-06-10 2004-12-23 Virco Bvba Computational method for predicting the contribution of mutations to the drug resistance phenotype exhibited by hiv based on a linear regression analysis of the log fold resistance
US7939310B2 (en) * 2003-08-06 2011-05-10 University Of Massachusetts Systems and methods for analyzing nucleic acid sequences
AU2005218183B2 (en) * 2004-03-02 2012-06-07 Virco Bvba Estimation of clinical cut-offs
EP2508621B1 (de) * 2005-11-29 2014-11-05 Children's Hospital Medical Center Optimierung und Individualisierung der Auswahl und Dosierung von Medikamenten
JP5297814B2 (ja) * 2006-02-03 2013-09-25 ビルコ・ビーブイビーエイ 量的ｈｉｖ表現型又は向性アッセイ
US20070265658A1 (en) * 2006-05-12 2007-11-15 Aga Medical Corporation Anchoring and tethering system
EP2126137B1 (de) 2007-01-23 2017-06-07 Janssen Pharmaceutica NV Verfahren zur erstellung eines arzneimittelplans für hiv-infizierte patienten
WO2008115427A2 (en) * 2007-03-16 2008-09-25 454 Life Sciences Corporation System and method for detection of hiv drug resistant variants
US20080293050A1 (en) * 2007-05-25 2008-11-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Gene analysis for determination of a treatment characteristic
US20100173282A1 (en) 2007-05-25 2010-07-08 Tibotec Pharmaceuticals Ltd. Mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance
US8793074B2 (en) * 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
US7888034B2 (en) * 2008-07-01 2011-02-15 454 Life Sciences Corporation System and method for detection of HIV tropism variants
US8296686B1 (en) 2008-10-14 2012-10-23 Handhold Adaptive, LLC Portable prompting aid for the developmentally disabled
WO2011098546A1 (en) 2010-02-12 2011-08-18 Tibotec Pharmaceuticals Computation of the combined potency of drug regimens from fitted or in vitro determined dose-response curves
JP5984822B2 (ja) * 2010-10-21 2016-09-06 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 注意欠陥多動性障害を有する患者を処置するための薬物を選択する方法
WO2012155148A2 (en) * 2011-05-12 2012-11-15 University Of Utah Research Foundation Predicting gene variant pathogenicity
EP2583680A3 (de) 2011-10-21 2013-06-12 Abbvie Inc. Einzel- (PSI-7977) oder Kombinationsbehandlung in der Verwendung zur Behandlung von HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2788490A1 (de) * 2011-12-05 2014-10-15 Duke University Identifizierung und klonen von übertragenen hepatitic-c-virus (hcv)-genomen durch einzelgenomamplifikation
US10679726B2 (en) 2012-11-26 2020-06-09 Koninklijke Philips N.V. Diagnostic genetic analysis using variant-disease association with patient-specific relevance assessment
WO2014110172A1 (en) * 2013-01-08 2014-07-17 Life Technologies Corporation Methods and systems for determining meta-genotypes
WO2014146048A2 (en) * 2013-03-15 2014-09-18 Laboratory Corporation Of America Holdings Methods for determining viral sensitivity to viral inhibitors
MX361092B (es) * 2013-05-23 2018-11-26 Iphenotype Llc Base de datos de búsqueda social integrada fenotípica y método.
US10144976B2 (en) 2014-05-22 2018-12-04 Case Western Reserve University HIV-1 genotyping and coreceptor tropism assay
WO2017012659A1 (en) * 2015-07-22 2017-01-26 Curetis Gmbh Genetic testing for predicting resistance of salmonella species against antimicrobial agents
WO2017016602A1 (en) * 2015-07-29 2017-02-02 Curetis Gmbh Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN111164224A (zh) * 2017-09-14 2020-05-15 普梭梅根公司 微生物相关的重要性指数指标

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6350311Y2 (de) 1984-11-16 1988-12-23
US5202259A (en) * 1986-05-20 1993-04-13 The Trustees Of Columbia University In The City Of New York Expression of human immunodeficiency virus (HIV) reverse transcriptase
AU675702B2 (en) 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
CN1209875A (zh) 1996-01-26 1999-03-03 维科公司 根据人类hiv病毒株的表型药物敏感性控制hiv阳性病人化疗的方法
AU719691B2 (en) * 1996-01-26 2000-05-18 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
WO1999040227A1 (en) 1998-02-10 1999-08-12 The Uab Research Foundation The use of hiv-1 integrase in screening hiv-1 drug candidates
WO1999061658A1 (en) 1998-05-26 1999-12-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
CA2341679A1 (en) 1998-06-24 1999-12-29 Virologic, Inc. Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
US6869759B1 (en) * 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
BR0011939A (pt) 1999-06-22 2002-03-12 Virologic Inc Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids
NZ518022A (en) 1999-08-27 2004-01-30 Iris Biotechnologies Inc Analysis and diagnosis by intelligent processing of remotely generated genetic hybridization profiles
WO2001057245A2 (en) 2000-02-04 2001-08-09 K.U.Leuven Research & Development Hiv-1 resistance assay
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network

Also Published As

Publication number Publication date
JP2004500836A (ja) 2004-01-15
ES2373488T3 (es) 2012-02-06
EP2011889B1 (de) 2011-09-28
US20070166747A1 (en) 2007-07-19
WO2001079540A2 (en) 2001-10-25
ES2312436T3 (es) 2009-03-01
WO2001079540A3 (en) 2003-06-05
US20020091664A1 (en) 2002-07-11
ATE526423T1 (de) 2011-10-15
DE60135366D1 (de) 2008-09-25
US7206699B2 (en) 2007-04-17
EP1332231A2 (de) 2003-08-06
AU2001260224A1 (en) 2001-10-30
EP2011889A1 (de) 2009-01-07
CA2406140A1 (en) 2001-10-25
US20040137436A1 (en) 2004-07-15
JP5156163B2 (ja) 2013-03-06
EP1332231B1 (de) 2008-08-13

Similar Documents

Publication Publication Date Title
ATE404698T1 (de) Methode zur bestimmung der resistenz gegen medikamente
Kim et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea
Sager et al. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification
Carr et al. Outcome series series editors: dl scott and a. Silman: quality of life measures
Poynard et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin
Reyes-Gibby et al. Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes
US20140229495A1 (en) Method for processing genomic data
EP1244047A2 (de) Verfahren zum Bereitstellen von klinisch-diagnostischen Diensten
Choi et al. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B
TW200502394A (en) Biochemical methods for measuring metabolic fitness of tissues or whole organisms
Rao et al. Essential statistical methods for medical statistics
Singer et al. Interpreting viral deep sequencing data with GLUE
Kuo et al. Using acute kidney injury severity and scoring systems to predict outcome in patients with burn injury
Lin et al. Effect of hepatic impairment on OATP1B activity: quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs
Yamashita et al. aMAP score prediction of hepatocellular carcinoma occurrence and incidence‐free rate after a sustained virologic response in chronic hepatitis C
Kazmers et al. Familial clustering of erosive hand osteoarthritis in a large statewide cohort
Zarnitsyna et al. Advancing therapies for viral infections using mechanistic computational models of the dynamic interplay between the virus and host immune response
Lee et al. Genome-wide association study of quantitative biomarkers identifies a novel locus for Alzheimer’s disease at 12p12. 1
Wang et al. Circulating Mitochondrial DNA Content Associated with the Risk of Liver Cirrhosis: A Nested Case–Control Study
Schmidt Signs of the times: biomarkers in perspective
Mezzetti et al. A Bayesian compartmental model for the evaluation of 1, 3-butadiene metabolism
WO2004111907A3 (en) Computational method for predicting the contribution of mutations to the drug resistance phenotype exhibited by hiv based on a linear regression analysis of the log fold resistance
Hawkes et al. A clinically meaningful difference was generated for a performance measure of recovery from hip fracture
AU2003276727A8 (en) Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes
Takemura et al. Epigenetic clock analysis in methamphetamine dependence

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1332231

Country of ref document: EP